Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10.
AKR1B10 has been identified as a potential biomarker for human nonsmall cell lung carcinoma and as a tobacco exposure and response gene. AKR1B10 functions as an efficient retinal reductase in vitro and may regulate retinoic acid homeostasis. However, the possibility that this enzyme is able to activate polycyclic aromatic hydrocarbon (PAH) trans-dihydrodiols to form reactive and redox-active o-quinones has not been investigated to date. AKR1B10 was found to oxidize a wide range of PAH trans-dihydrodiol substrates in vitro to yield PAH o-quinones. Reactions of AKR1B10 proceeded with improper stereochemistry, since it was specific for the minor (+)-benzo[a]pyrene-7S,8S-dihydrodiol diastereomer formed in vivo. However, AKR1B10 displayed reasonable activity in the oxidation of both the (-)-R,R and (+)-S,S stereoisomers of benzo[g]chrysene-11,12-dihydrodiol and oxidized the potentially relevant, albeit minor, (+)-benz[a]anthracene-3S,4S-dihydrodiol metabolite. We find that AKR1B10 is therefore likely to play a contributing role in the activation of PAH trans-dihydrodiols in human lung. AKR1B10 retinal reductase activity was confirmed in vitro and found to be 5- to 150-fold greater than the oxidation of PAH trans-dihydrodiols examined. AKR1B10 was highly expressed at the mRNA and protein levels in human lung adenocarcinoma A549 cells, and robust retinal reductase activity was measured in lysates of these cells. The much greater catalytic efficiency of retinal reduction compared to PAH trans-dihydrodiol metabolism suggests AKR1B10 may play a greater role in lung carcinogenesis through dysregulation of retinoic acid homeostasis than through oxidation of PAH trans-dihydrodiols.
Quinn
Amy M
AM
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6084, USA.
Harvey
Ronald G
RG
Penning
Trevor M
TM
D000449:Aldehyde Reductase / Q000032:analysis / Q000502:physiology*; D000074408:Aldo-Keto Reductases; D002273:Carcinogens / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology; D002478:Cells, Cultured; D002942:Circular Dichroism; D004101:Dihydroxydihydrobenzopyrenes / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000209:etiology; D010084:Oxidation-Reduction; D011084:Polycyclic Aromatic Hydrocarbons / Q000378:metabolism*; D012172:Retinaldehyde / Q000378:metabolism
D002273:Carcinogens; D004101:Dihydroxydihydrobenzopyrenes; D011084:Polycyclic Aromatic Hydrocarbons; C017228:benzo(a)pyrene 7,8-dihydrodiol; C120471:AKR1B10 protein, human; D000074408:Aldo-Keto Reductases; D000449:Aldehyde Reductase; D012172:Retinaldehyde
J Org Chem. 2004 Mar 19;69(6):2024-32
15058949
Int J Cancer. 2007 Nov 15;121(10):2301-6
17597105
Chem Res Toxicol. 1996 Jan-Feb;9(1):84-92
8924621
Free Radic Biol Med. 2000 Jul 1;29(1):17-25
10962201
Carcinogenesis. 1998 Nov;19(11):1889-94
9854998
J Natl Cancer Inst. 1997 May 7;89(9):624-9
9150186
J Clin Endocrinol Metab. 1998 Aug;83(8):2886-91
9709964
Chem Res Toxicol. 1993 May-Jun;6(3):252-60
7686407
Cancer Res. 2000 Feb 15;60(4):908-15
10706104
J Natl Cancer Inst. 2005 Nov 16;97(22):1645-51
16288117
Biochemistry. 1996 Oct 22;35(42):13664-72
8885846
Cancer Res. 1997 Nov 1;57(21):4931-9
9354460
Environ Sci Technol. 2005 Jan 15;39(2):471-8
15707046
Nature. 1990 Jan 11;343(6254):177-80
2153268
Chem Biol Interact. 1984 Apr;49(1-2):71-88
6722941
FASEB J. 1997 Feb;11(2):181-8
9039961
Toxicol Lett. 2004 Sep 25;152(3):235-43
15331132
Cancer Prev Res (Phila). 2008 Jul;1(2):80-3
19138939
EMBO J. 1989 Feb;8(2):429-33
2542014
Mol Carcinog. 1993;8(2):112-22
7691069
Clin Cancer Res. 2005 Mar 1;11(5):1776-85
15755999
Arch Biochem Biophys. 2007 Aug 15;464(2):241-50
17537398
Xenobiotica. 1996 Sep;26(9):909-19
8893038
Chem Biol Interact. 1979 Oct;27(2-3):145-61
498352
Biochemistry. 2001 Sep 11;40(36):10901-10
11535067
Mol Cell Endocrinol. 2008 Jan 16;281(1-2):1-8
18060684
Cancer Res. 1995 Dec 1;55(23):5603-10
7585641
Nutr Rev. 1999 Sep;57(9 Pt 1):263-72
10568335
IARC Monogr Eval Carcinog Risk Chem Hum. 1983 Dec;32:1-453
6586639
Biochem J. 2006 Oct 1;399(1):101-9
16787387
J Nutr. 2000 Feb;130(2S Suppl):479S-482S
10721933
Chem Res Toxicol. 2008 May;21(5):1086-94
18402469
Cancer Res. 2007 Aug 1;67(15):7431-8
17671213
Chem Res Toxicol. 2005 Feb;18(2):365-74
15720144
N Engl J Med. 1996 May 2;334(18):1150-5
8602180
Lung Cancer. 2004 Sep;45(3):289-97
15301869
Carcinogenesis. 1982;3(2):215-7
7067048
Biochem J. 1999 Oct 15;343 Pt 2:487-504
10510318
Cancer Prev Res (Phila). 2008 Jul;1(2):112-8
19138944
Cell Prolif. 2007 Jun;40(3):411-21
17531084
Endocrinology. 2006 Dec;147(12):5806-16
16959841
N Engl J Med. 1994 Apr 14;330(15):1029-35
8127329
J Biol Chem. 2002 Jul 5;277(27):24799-808
11978787
Chem Biol Interact. 1983 Jul 1;45(1):15-28
6872097
Biochemistry. 1998 May 12;37(19):6781-90
9578563
Pharmacol Ther. 1992;54(1):63-128
1528955
Proc Natl Acad Sci U S A. 2008 May 13;105(19):6846-51
18474869
Chem Res Toxicol. 2006 Jan;19(1):68-78
16411658
Cancer Res. 2004 Dec 15;64(24):9027-34
15604268
Biochem J. 2003 Aug 1;373(Pt 3):973-9
12732097
J Biol Chem. 1993 Dec 5;268(34):25687-93
8245005
J Natl Cancer Inst. 1999 Jun 16;91(12):1059-66
10379969
J Neurobiol. 2006 Jun;66(7):606-30
16688755
FASEB J. 1989 Jun;3(8):1927-32
2656356
J Biol Chem. 1998 May 8;273(19):11429-35
9565553
Carcinogenesis. 1991 Oct;12(10):1939-44
1934274
Carcinogenesis. 2005 Mar;26(3):525-30
15618235
Toxicol Lett. 2006 Aug 20;165(2):182-94
16713138
J Pathol. 2006 Oct;210(2):192-204
16915569
Am Ind Hyg Assoc J. 1965 Sep-Oct;26(5):475-8
5865317
Chem Res Toxicol. 2006 May;19(5):719-28
16696575
Cancer Prev Res (Phila). 2008 Jul;1(2):100-11
19138943
Hepatology. 2004 Feb;39(2):540-9
14768008